Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239121 | 0.86 | P2RX4 (0.49) | P2RX4RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL16239101 | 0.86 | P2RX4 (0.51) | P2RX4MEN1KMT2ATDP1 | |
| SCHEMBL16239011 | 0.85 | P2RX4 (0.49) | P2RX4RAB9ANPC1MEN1KMT2A | |
| SCHEMBL16239113 | 0.85 | P2RX4 (0.51) | P2RX4 | |
| SCHEMBL16239149 | 0.85 | P2RX4 (0.48) | P2RX4RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL16238946 | 0.84 | P2RX4 (0.49) | P2RX4RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL16239138 | 0.84 | P2RX4 (0.48) | P2RX4RAB9ANPC1LMNAMAPT | |
| SCHEMBL16239015 | 0.83 | P2RX4 (0.48) | P2RX4RAB9ALMNAMAPT | |
| SCHEMBL16267380 | 0.82 | P2RX4 (0.48) | P2RX4RAB9ANPC1GRM5MAPT | |
| SCHEMBL16238993 | 0.81 | P2RX4 (0.51) | P2RX4RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-03-05 | — | — | US | claimed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | claimed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | claimed |
| WO-2023157895-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ENDOMETRIOSIS OR ADENOMYOSIS | 国立大学法人 鳥取大学 | 2023-08-24 | — | — | WO | claimed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | claimed |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-18 | — | — | US | claimed |
| WO-2023054578-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | 日本ケミファ株式会社 | 2023-04-06 | — | — | WO | claimed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | claimed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | claimed |
| EP-3848051-A1 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | Nippon Chemiphar Co., Ltd. (JP) | 2021-07-14 | — | — | EP | claimed |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-04-29 | — | — | US | claimed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | claimed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | claimed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | claimed |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | TRPM4, TRPM7, P2RX3 | P2RX4 5/4885RAB9A 4610/4885NPC1 925/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885RAB9A 3462/4885NPC1 2397/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885RAB9A 3462/4885NPC1 2397/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885RAB9A 3462/4885NPC1 2397/4885 |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | P2RX3, TRPM4, P2RX4 | P2RX4 3/4885RAB9A 4637/4885NPC1 1013/4885 |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | P2RX5, P2RX3, P2RX2 | P2RX4 4/4885RAB9A 1996/4885NPC1 741/4885 |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 5/4885RAB9A 3227/4885NPC1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.